All In Biotech

Free tool

FAERS Monitor: Mavyret

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215110 or its brand name (Mavyret, Glecaprevir, Pibrentasvir). Reports on generic versions are filed under their own applications.

Reports

10,976

Serious

2,823

26% of reports

Hospitalization

1,325

Death reported

296

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue2,568
  • headache2,208
  • nausea1,135
  • pruritus662
  • diarrhoea481
  • vomiting317
  • rash314
  • dizziness232
  • death231
  • pain211
  • insomnia201
  • abdominal discomfort199
  • drug ineffective193
  • asthenia158
  • abdominal pain upper149

Reports by year received

View as table
YearReports
2017156
20183,515
20193,713
20201,203
2021526
2022715
2023437
2024282
2025266
2026163

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,043,183 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
headacheSignal2,2086.86.511,144
fatigueSignal2,5686.36.111,945
pruritusSignal6623.33.11,080
nauseaSignal1,1352.82.61,310
abdominal discomfortSignal1992.32.0142
insomnia2011.41.328
diarrhoea4811.41.363
abdominal pain upper1491.41.216
rash3141.41.233
vomiting3171.31.221
dizziness2320.90.83
asthenia1580.80.77
pain2110.70.638
death2310.50.5110
drug ineffective1930.30.2379

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.